Tech Company Financing Transactions
Locus Biosciences Funding Round
Locus Biosciences closed a $5 million financing round on 7/11/2017. Investors included Tencent Holdings and North Carolina Biotechnology Center.
Transaction Overview
Company Name
Announced On
7/11/2017
Transaction Type
Debt
Amount
$5,000,000
Round
Undisclosed
Investors
Tencent Holdings (Lead Investor)
Proceeds Purpose
This funding will advance multiple infectious disease product programs targeting antibiotic resistant infections and other microbiome-related diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
523 Davis Dr. 350
Morrisville, NC 27560
USA
Morrisville, NC 27560
USA
Phone
Website
Email Address
Overview
Locus Biosciences is an emerging biotechnology company focused on the discovery and development of a next generation CRISPR-Cas platform for precision antimicrobials. Our novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Garofolo
Chief Scientific Officer
David Ousterout
VP - Bus. Development
Paul Kim
VP - Bus. Development
Joseph Nixon
VP - Operations
Jamie Kime
Browse more venture capital transactions:
Prev: 7/11/2017: Telestax venture capital transaction
Next: 7/11/2017: VoltServer venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs